No profile data available.
Telomir Pharmaceuticals, Inc. (TELO) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Miami, United States.
It reported revenue of $0 for fiscal year 2024, and net income of -$16.53 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $82.45 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
Telomir Pharmaceuticals reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$82.45 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include vTv Therapeutics Inc. (VTVT), Vivani Medical, Inc. (VANI), Revium Rx (RVRC), XBiotech Inc. (XBIT).